Calidi Biotherapeutics' Warrant Exercise Announcement
Calidi Biotherapeutics, Inc. (NASDAQ: CLDI), known for its innovative approaches in biotechnology, recently made a noteworthy announcement regarding the immediate exercise of various outstanding warrants. This strategic move is expected to bolster the company with approximately $4.6 million in gross proceeds, signifying a strong position in the biotechnology sector.
Details of the Warrant Exercise
The warrants in question include Series A, B-1, C-1, D, E, and F Warrants, totaling up to 6,595,000 shares of the company's common stock. The reduced exercise price is set at $0.70 per share. Calidi has appointed Ladenburg Thalmann & Co, Inc. as the exclusive placement agent for this offering, ensuring a smooth process.
New Warrants Issuance
Upon the immediate exercise of these existing warrants, Calidi will issue new unregistered warrants of the same quantity. These new instruments will also have an exercise price of $0.70 per share and come with a six-month exercise period following their issuance, alongside a term of a robust five and a half years. This initiative exemplifies Calidi's proactive approach to funding its innovative projects and research.
Intended Use of Proceeds
The net proceeds from this offering, estimated post-deductions, will primarily support Calidi's ongoing clinical and pre-clinical programs. This includes essential works on advancing their pioneering targeted therapies, which have shown promise in addressing significant medical needs in oncology.
Significance of the Funding
This round of funding is particularly crucial as it allows Calidi Biotherapeutics to enhance its operational capabilities, focusing on pushing forward their groundbreaking research and development efforts in genetic medicines. Such strategic financial maneuvers are essential for sustaining the momentum of innovation within the company.
Projecting Future Developments
Looking ahead, the company aims to fortify its position in the biotechnology landscape as it strives toward achieving critical milestones. The anticipated closing of this offering highlights a clear roadmap for Calidi's future actions, fortifying its resources to navigate upcoming clinical trials.
Regulatory Compliance
The new warrants will be offered under the applicable sections of the Securities Act, ensuring they conform to market regulations. Calidi is committed to adhering to these standards, ensuring that the shares issued can be traded effectively while maintaining compliance with the SEC's guidelines.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NASDAQ: CLDI) is a pioneer in developing targeted therapies aimed at delivering genetic medicines to challenges in oncology. Their proprietary Redtail platform showcases over a decade of expertise in devising viral vectors engineered to evade immune detection, significantly enhancing the efficacy of their treatment modalities.
Breakthrough Development Efforts
The flagship candidate from the Redtail platform is currently undergoing IND-enabling studies aimed at combatting non-small cell lung cancer, ovarian cancer, and other high-need tumor types. With their focus on administering protected virotherapies, Calidi is dedicated to revolutionizing the landscape of cancer treatment.
Corporate Communication
For inquiries, investors, and media are encouraged to contact Dave Gentry, CEO of RedChip Companies, Inc. He can be reached at 1-407-644-4256 or via email at CLDI@redchip.com. This direct line of communication is vital for stakeholders eager to learn more about Calidi's advancements and strategic initiatives.
Frequently Asked Questions
What is the purpose of the warrant exercise announced by Calidi?
The warrant exercise aims to generate approximately $4.6 million to fund ongoing clinical and pre-clinical programs at Calidi Biotherapeutics.
How many shares are involved in the warrant exercise?
A total of 6,595,000 shares of common stock are included in the warrant exercise.
What is the exercise price for the new warrants?
The exercise price for the new warrants is set at $0.70 per share.
Who is acting as the placement agent for this offering?
Ladenburg Thalmann & Co, Inc. is serving as the exclusive placement agent for the warrant exercise.
What will the proceeds from the warrant exercise be used for?
The proceeds will be utilized to advance clinical and pre-clinical programs and to support the company's operational and working capital needs.
